GAD2

Across TCGA pan-cancer cohorts, GAD2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GAD2 data layer compared with 18 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher GAD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GAD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

READ, UCEC, and SCLC are the cancer types where GAD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.111	0.919	<.001	30	view →
UCEC	DFS	Median	II,III,IV	0.937	0.434	.013	28	view →
SCLC	DFS	Median	II,III,IV	0.137	0.562	.013	9	view →
LGG	OS	Median	All	0.317	0.811	.016	6	view →
COAD	OS	Median	IV	0.263	0.665	.028	6	view →
SKCM	OS	Median	III,IV	0.128	0.446	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GAD2–READ (OS)

Open the READ breakdown →